Geneva, Switzerland (PRWEB) May 30, 2012
Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that representatives from the Company will be participating in the 2012 BIO International Convention's One-on-One Partnering Meetings being held June 18-21 in Boston, MA at the Boston Convention & Exhibition Center.
Selexis has developed a suite of services and technologies within the SUREtechnology Platform™ that speed and boost productivity of manufacturing cell lines, improve outcomes in biologics drug discovery and lead identification and overcome bottlenecks in difficult-to-express proteins. Selexis has interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide in wide range of areas including bio-manufacturing, drug discovery, diagnostics and therapeutics.
Representatives available to discuss Selexis’ capabilities include: Dr. Igor Fisch, CEO; Dr. Armelle Gaussin, Chief Technology Officer; Andrew Sandford, VP Business Development and Licensing; and Yemi Onakunle VP Strategic and Market Development. Companies or individuals attending BIO 2012 can schedule meetings with Selexis by visiting (registration required): http://oneononepartnering.bio.org/BusinessForum2012/
Selexis Partnering Schedule:
Monday, June 18 Business Forum - 8:00 AM – 5:00 PM
Tuesday, June 19 Business Forum - 8:00 AM – 5:00 PM
Wednesday, June 20 Business Forum - 8:00 AM – 5:00 PM
Thursday, June 21 Business Forum - 8:00 AM – 12:00 PM
For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1102 located in Hall A – Discovery Zone (http://www.mapyourshow.com/shows/index.cfm?show_id=bio12).
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.
For more information: